Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chem...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncoimmunology
Κύριοι συγγραφείς: Hardy-Werbin, Max, Rocha, Pedro, Arpi, Oriol, Taus, Álvaro, Nonell, Lara, Durán, Xavier, Villanueva, Xavier, Joseph-Pietras, Deborah, Nolan, Luke, Danson, Sarah, Griffiths, Richard, Lopez-Botet, Miguel, Rovira, Ana, Albanell, Joan, Ottensmeier, Christian, Arriola, Edurne
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Taylor & Francis 2019
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492977/
https://ncbi.nlm.nih.gov/pubmed/31069160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1593810
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια